

Birgitte Fagerlund

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9358534/publications.pdf>

Version: 2024-02-01

129
papers

2,491
citations

185998

28
h-index

253896

43
g-index

137
all docs

137
docs citations

137
times ranked

4167
citing authors

#	ARTICLE	IF	CITATIONS
1	Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. <i>Biological Psychiatry</i> , 2018, 83, 492-498.	0.7	374
2	Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). <i>BMJ: British Medical Journal</i> , 2017, 356, i6681.	2.4	79
3	Social cognition and neurocognitive deficits in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2014, 153, 9-17.	1.1	76
4	Do Attention Deficits Influence IQ Assessment in Children and Adolescents With ADHD?. <i>Journal of Attention Disorders</i> , 2009, 12, 551-562.	1.5	71
5	Cognitive function in idiopathic intracranial hypertension: a prospective case-control study. <i>BMJ Open</i> , 2014, 4, e004376.	0.8	71
6	Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders. <i>Schizophrenia Research</i> , 2006, 85, 30-39.	1.1	61
7	Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. <i>Schizophrenia Research</i> , 2016, 175, 57-63.	1.1	61
8	Subclinical cognitive decline in middle age is associated with reduced task-induced deactivation of the brain's default mode network. <i>Human Brain Mapping</i> , 2014, 35, 4488-4498.	1.9	51
9	Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2007, 30, 3-12.	0.2	49
10	Subjective sleep quality and daytime sleepiness in late midlife and their association with age-related changes in cognition. <i>Sleep Medicine</i> , 2016, 17, 165-173.	0.8	49
11	Effects of Low-Dose Risperidone and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic Patients. <i>CNS Spectrums</i> , 2004, 9, 364-374.	0.7	48
12	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. <i>Schizophrenia Research: Cognition</i> , 2016, 5, 21-27.	0.7	46
13	Cognitive Profile of Children and Adolescents with Anorexia Nervosa. <i>European Eating Disorders Review</i> , 2015, 23, 34-42.	2.3	42
14	The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms.. <i>Neuropsychology</i> , 2017, 31, 209-219.	1.0	41
15	The Relationship Between Cognitive Ability and Demographic Factors in Late Midlife. <i>Journal of Aging and Health</i> , 2014, 26, 37-53.	0.9	40
16	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 25.	0.7	40
17	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. <i>Lancet Psychiatry</i> , 2017, 4, 605-618.	3.7	40
18	The influence of impaired processing speed on cognition in first-episode antipsychotic-naïve schizophrenic patients. <i>European Psychiatry</i> , 2013, 28, 332-339.	0.1	38

#	ARTICLE	IF	CITATIONS
19	Hyper- and Hypometalizing in Patients with First-Episode Schizophrenia: fMRI and Behavioral Studies. <i>Schizophrenia Bulletin</i> , 2019, 45, 377-385.	2.3	38
20	Structural brain abnormalities in early onset first-episode psychosis. <i>Journal of Neural Transmission</i> , 2007, 114, 489-498.	1.4	37
21	No cognitive-enhancing effect of <sc>GLP</sc>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 52-62.	2.2	36
22	Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 278-287.	0.7	36
23	Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1035-e1046.	1.1	36
24	Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 163-171.	1.8	35
25	Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. <i>Translational Psychiatry</i> , 2017, 7, e1087-e1087.	2.4	32
26	Stability of prepulse inhibition and habituation of the startle reflex in schizophrenia: a 6-year follow-up study of initially antipsychotic-naive, first-episode schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 913-925.	1.0	31
27	Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD. <i>Psychological Medicine</i> , 2017, 47, 377-388.	2.7	30
28	Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. <i>BMC Psychiatry</i> , 2011, 11, 160.	1.1	28
29	Melatonin and cortisol profiles in late midlife and their association with age-related changes in cognition. <i>Nature and Science of Sleep</i> , 2016, 8, 47.	1.4	28
30	Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study. <i>Neuropsychopharmacology</i> , 2019, 44, 581-589.	2.8	28
31	Deficient maturation of aspects of attention and executive functions in early onset schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 773-786.	2.8	25
32	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 250-258.	2.2	25
33	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012, 10, 92.	2.3	24
34	A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data. <i>Translational Psychiatry</i> , 2020, 10, 276.	2.4	24
35	Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Caseâ€Control Study. <i>NeuroMolecular Medicine</i> , 2015, 17, 423-430.	1.8	23
36	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. <i>Schizophrenia Research</i> , 2020, 224, 151-158.	1.1	23

#	ARTICLE	IF	CITATIONS
37	Is an Early Age at Illness Onset in Schizophrenia Associated With Increased Genetic Susceptibility? Analysis of Data From the Nationwide Danish Twin Register. <i>EBioMedicine</i> , 2017, 18, 320-326.	2.7	22
38	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. <i>Human Brain Mapping</i> , 2019, 40, 5185-5201.	1.9	22
39	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , 2014, 4, e004158.	0.8	20
40	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 1332-1340.	2.3	20
41	Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients. <i>Psychological Medicine</i> , 2019, 49, 2754-2763.	2.7	20
42	Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D _{2/3} receptor antagonist treatment. <i>Psychological Medicine</i> , 2019, 49, 754-763.	2.7	19
43	Course of intelligence deficits in early onset, first episode schizophrenia: a controlled, 5-year longitudinal study. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 341-351.	2.8	18
44	Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. <i>Psychiatry Research</i> , 2011, 187, 49-54.	1.7	18
45	Relationship of frontal D2/3 binding potentials to cognition: a study of antipsychotic-naïve schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 23-36.	1.0	18
46	Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. <i>World Psychiatry</i> , 2020, 19, 401-402.	4.8	18
47	Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study. <i>Psychological Medicine</i> , 2022, 52, 1101-1114.	2.7	18
48	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2019, 49, 868-875.	2.7	18
49	Are Weight Status and Cognition Associated? An Examination of Cognitive Development in Children and Adolescents with Anorexia Nervosa 1 Year after First Hospitalisation. <i>European Eating Disorders Review</i> , 2016, 24, 366-376.	2.3	17
50	Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw006.	1.0	17
51	Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12-43 years. <i>Psychological Medicine</i> , 2021, 51, 1570-1580.	2.7	17
52	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1062-1078.	0.3	16
53	Heritability of Cerebral Blood Flow and the Correlation to Schizophrenia Spectrum Disorders: A Pseudo-continuous Arterial Spin Labeling Twin Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 1231-1241.	2.3	16
54	Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder. <i>Psychological Medicine</i> , 2018, 48, 604-616.	2.7	14

#	ARTICLE	IF	CITATIONS
55	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2019, 210, 197-202.	1.1	13
56	Investigation of sleep spindle activity and morphology as predictors of neurocognitive functioning in medicated patients with schizophrenia. <i>Journal of Sleep Research</i> , 2019, 28, e12672.	1.7	13
57	Patterns of Cortical Structures and Cognition in Antipsychotic-Naïve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 444-453.	1.1	12
58	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. <i>Psychological Medicine</i> , 2020, 50, 1475-1489.	2.7	12
59	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 569-579.	1.1	12
60	Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 997-1006.	1.0	11
61	Discovering markers of healthy aging: a prospective study in a Danish male birth cohort. <i>Aging</i> , 2019, 11, 5943-5974.	1.4	11
62	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	1.1	10
63	Cognitive Change during the Life Course and Leukocyte Telomere Length in Late Middle-Aged Men. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 300.	1.7	10
64	Attenuated mismatch negativity in patients with first-episode antipsychotic-naïve schizophrenia using a source-resolved method. <i>NeuroImage: Clinical</i> , 2019, 22, 101760.	1.4	10
65	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. <i>Brain and Behavior</i> , 2021, 11, e01962.	1.0	10
66	Testing a decades-old assumption: Are individuals with lower sensory gating indeed more easily distracted?. <i>Psychiatry Research</i> , 2017, 255, 387-393.	1.7	9
67	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis: A Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 873.	1.3	9
68	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 448-463.	2.2	9
69	Increased deoxythymidine triphosphate levels is a feature of relative cognitive decline. <i>Mitochondrion</i> , 2015, 25, 34-37.	1.6	8
70	Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia. <i>European Psychiatry</i> , 2019, 62, 130-137.	0.1	8
71	Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment. <i>Psychological Medicine</i> , 2019, 49, 2617-2625.	2.7	8
72	Sleep efficiency and neurophysiological patterns in middle-aged men are associated with cognitive change over their adult life course. <i>Journal of Sleep Research</i> , 2019, 28, e12793.	1.7	8

#	ARTICLE	IF	CITATIONS
73	The impact of schizophrenia and intelligence on the relationship between age and brain volume. <i>Schizophrenia Research: Cognition</i> , 2019, 15, 1-6.	0.7	8
74	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. <i>Frontiers in Pharmacology</i> , 2020, 11, 591.	1.6	8
75	The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study. <i>Psychological Medicine</i> , 2023, 53, 1266-1276.	2.7	8
76	Subclinical cognitive deficits are associated with reduced cerebrovascular response to visual stimulation in mid-sixties men. <i>GeroScience</i> , 2022, 44, 1905-1923.	2.1	8
77	Influence of early life characteristics on psychiatric admissions and impact of psychiatric disease on inflammatory biomarkers and survival: a Danish cohort study. <i>World Psychiatry</i> , 2015, 14, 364-365.	4.8	7
78	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	1.5	7
79	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. <i>European Psychiatry</i> , 2020, 63, e83.	0.1	7
80	Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, , .	0.3	7
81	Passive Double-Sensory Evoked Coherence Correlates with Long-Term Memory Capacity. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 598.	1.0	6
82	Do young adolescents with first-episode psychosis or ADHD show sensorimotor gating deficits?. <i>Psychological Medicine</i> , 2020, 50, 607-615.	2.7	6
83	Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 649-655.	2.8	6
84	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. <i>Psychiatry Research</i> , 2020, 290, 112969.	1.7	6
85	Multimodal assessment of white matter microstructure in antipsychotic-naïve schizophrenia patients and confounding effects of recreational drug use. <i>Brain Imaging and Behavior</i> , 2021, 15, 36-48.	1.1	6
86	Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood—A Randomized Clinical Trial. <i>Child Development</i> , 2021, 92, 1624-1635.	1.7	6
87	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2021, 237, 192-201.	1.1	6
88	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. <i>Schizophrenia Research</i> , 2018, 195, 562-563.	1.1	5
89	Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysis. <i>Cortex</i> , 2021, 139, 282-297.	1.1	5
90	Profile of cognitive deficits and associations with depressive symptoms and intelligence in chronic early-onset schizophrenia patients. <i>Scandinavian Journal of Psychology</i> , 2013, 54, 363-370.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. <i>European Neuropsychopharmacology</i> , 2021, 46, 83-92.	0.3	4
92	Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYPH study protocol. <i>BMJ Open</i> , 2022, 12, e047706.	0.8	4
93	Cortico-cognition coupling in treatment resistant schizophrenia. <i>NeuroImage: Clinical</i> , 2022, 35, 103064.	1.4	4
94	Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms. <i>Psychiatry Research</i> , 2020, 294, 113498.	1.7	3
95	Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	3
96	Association of neurocognitive functioning with sleep stage dissociation and REM sleep instability in medicated patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 136, 198-203.	1.5	3
97	Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-naïve, adult ADHD patients. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	3
98	Reward Processing as an Indicator of Vulnerability or Compensatory Resilience in Psychoses? Results From a Twin Study. <i>Biological Psychiatry Global Open Science</i> , 2023, 3, 47-55.	1.0	3
99	Add-On MEmantine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	3
100	SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity. <i>Schizophrenia Bulletin</i> , 2017, 43, S167-S167.	2.3	2
101	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 667-672.	0.7	2
102	Discovering correlates of age-related decline in a healthy late-midlife male birth cohort. <i>Aging</i> , 2020, 12, 16709-16743.	1.4	2
103	A nation-wide twin study of social cognition in schizophrenia spectrum disorders. <i>NPJ Schizophrenia</i> , 2022, 8, 12.	2.0	2
104	Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 102-107.	0.7	2
105	THE COURSE OF COGNITIVE DEFICITS IN SCHIZOPHRENIA FROM ILLNESS ONSET TO 6 YEARS POST ONSET: PRELIMINARY RESULTS FROM A PROSPECTIVE LONGITUDINAL STUDY. <i>Schizophrenia Research</i> , 2010, 117, 211.	1.1	1
106	Association of the CHRNA7 promoter variant 86T with Tourette syndrome and comorbid obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2014, 219, 710-711.	1.7	1
107	O4.5. EXPLORING THE RELATIONSHIP BETWEEN SENSORY FILTERING AND COGNITION: RESULTS OF A LARGE COHORT OF ANTIPSYCHOTIC-NAÏVE FIRST-EPISEDE SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , 2019, 45, S170-S171.	2.3	1
108	4.1 COGNITIVE RESERVE ATTENUATES AGE-RELATED COGNITIVE DECLINE IN THE CONTEXT OF ACCELERATED BRAIN AGEING IN SCHIZOPHRENIA-SPECTRUM DISORDERS: EVIDENCE FOR ACTIVE COMPENSATION. <i>Schizophrenia Bulletin</i> , 2019, 45, S91-S92.	2.3	1

#	ARTICLE	IF	CITATIONS
109	O4.6. HERITABILITY OF SPECIFIC COGNITIVE FUNCTIONS AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS USING CANTAB: A NATION-WIDE TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2019, 45, S171-S171.	2.3	1
110	Structural gray matter brain abnormalities in first-episode early onset psychosis: A voxel based morphometry study in children and adolescents aged ten to eighteen. <i>Schizophrenia Research</i> , 2003, 60, 204.	1.1	0
111	EXTRASTRIATAL DOPAMINE D2 RECEPTOR BINDING POTENTIALS IN ANTIPSYCHOTIC-NAÏVE FIRST-EPISEODE SCHIZOPHRENIC PATIENTS. <i>Schizophrenia Research</i> , 2008, 102, 42.	1.1	0
112	Poster #64 RECRUITMENT STATUS OF THE TEA TRIAL: TOLERANCE AND EFFECT OF ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. AN INVESTIGATOR-INITIATED, PHASE IV, RANDOMISED DOUBLE-BLIND MULTI-CENTRE TRIAL OF THE BENEFITS AND HARMS OF ARIPIRAZOLE VERSUS QUETIAPINE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS. <i>Schizophrenia Research</i> , 2012, 136, S208.	1.1	0
113	Cognitive function patients with idiopathic intracranial hypertension. <i>Journal of the Neurological Sciences</i> , 2013, 333, e483.	0.3	0
114	P201: Late midlife sleep pattern and sleep structure and the association to age-related changes in cognition. <i>Clinical Neurophysiology</i> , 2014, 125, S101.	0.7	0
115	4.17 QUETIAPINE EXTENDED RELEASE VERSUS ARIPIRAZOLE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS IN THE RANDOMIZED, BLINDED CLINICAL TOLERABILITY AND EFFICACY OF ANTIPSYCHOTICS (TEA) TRIAL. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S168.	0.3	0
116	â€˜No cognitiveâ€™enhancing effect of <sc>GLP</sc>â€™1 receptor agonism in antipsychoticâ€™treated, obese patients with schizophreniaâ€™™: authors' response. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 526-527.	2.2	0
117	48. Associations Between Electrophysiological Measures of Selective Attention and Neurocognitive Measures of Working Memory and Attention in Antipsychotic-Naive, First-Episode Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2017, 43, S26-S26.	2.3	0
118	SA37. Cognition and White Matter Integrity in Antipsychotic-Naive First-Episode Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2017, 43, S126-S127.	2.3	0
119	O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S80-S80.	2.3	0
120	F21. ELECTROPHYSIOLOGICAL PARAMETERS OF SELECTIVE ATTENTION IN ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS: A COMPARISON WITH ADHD. <i>Schizophrenia Bulletin</i> , 2018, 44, S226-S227.	2.3	0
121	F34. AUDITORY SENSORY GATING IN YOUNG ADOLESCENTS WITH EARLY-ONSET PSYCHOSIS: A COMPARISON WITH ADHD. <i>Schizophrenia Bulletin</i> , 2018, 44, S232-S232.	2.3	0
122	F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAÏVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST. <i>Schizophrenia Bulletin</i> , 2018, 44, S289-S289.	2.3	0
123	T88. THE IMPACT OF AGE OF ONSET AND ILLNESS DURATION ON WHITE MATTER AND COGNITION TRAJECTORIES IN SCHIZOPHRENIA: A 7-YEAR FOLLOW-UP STUDY ACROSS MULTIPLE TIME-POINTS. <i>Schizophrenia Bulletin</i> , 2019, 45, S237-S238.	2.3	0
124	T97. PATTERNS OF COGNITIVE FUNCTION ARE UNIQUELY ASSOCIATED WITH WHITE MATTER-MICROSTRUCTURE IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S241-S242.	2.3	0
125	S15. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDERS OF CEREBRAL BLOOD FLOW MEASURED BY PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING IN DANISH TWINS. <i>Schizophrenia Bulletin</i> , 2019, 45, S311-S311.	2.3	0
126	O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISEODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL. <i>Schizophrenia Bulletin</i> , 2019, 45, S197-S197.	2.3	0

#	ARTICLE	IF	CITATIONS
127	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. <i>Child and Adolescent Mental Health</i> , 2020, 25, 79-94.	1.8	0
128	T46. THE EFFECT OF COMPREHENSIVE COGNITIVE REMEDIATION IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: A SINGLE-BLIND, RANDOMISED, CLINICAL TRIAL (FOCUS). <i>Schizophrenia Bulletin</i> , 2020, 46, S249-S249.	2.3	0
129	T60. GENETIC INFLUENCES ON MEMORY FUNCTIONS AND RELATED BRAIN STRUCTURES AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS: A NATION-WIDE TWIN STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S254-S254.	2.3	0